Prevalence of myositis specific autoantibodies and myositis associated autoantibodies in serum samples from European patients with myositis
| Autoantibodies | Tests |
Number of PM1-152 sera (%) |
Number of DM1-152 sera (%) |
Number of IBM1-152sera (%) |
Total number of sera (%) | Prevalence (%) reported in refs 5, 28, 37 |
| 198 (100) | 181 (100) | 38 (100) | 417 (100) | |||
| Myositis specific autoantibodies | ||||||
| Anti-synthetase antibodies | ||||||
| Anti-His-tRNA synthetase (Jo-1) | ELISA, IB1-152, IP1-152 | 43 (22) | 28 (16) | 2 (5) | 73 (18) | (17–29) |
| Anti-tRNAHis | IP | 18 (9) | 7 (4) | 1 (3) | 26 (6) | ND1-150 |
| Other anti-synthetases | IP | 6 (3) | 5 (3) | 1 (3) | 12 (3) | (6–7) |
| Anti-tRNA (other) | IP | 2 (1) | 0 | 0 | 2 (0.5) | (1)1-150 |
| Anti-signal recognition particle (SRP) | Dotblot | 14 (7) | 5 (3) | 1 (3) | 20 (5) | (3–6) |
| Antinuclear helicase/ATPase (Mi-2) | ELISA | 17 (9) | 38 (21) | 3 (8) | 58 (14) | (4–5)1-151 |
| Myositis associated autoantibodies | ||||||
| Anti-exosome complex | (0–4) | |||||
| Anti-PM/Scl-100 | ELISA | 13 (7) | 10 (6) | 0 | 23 (6) | |
| Anti-PM/Scl-75 | ELISA | 5 (3) | 6 (3) | 0 | 11 (3) | |
| Anti-tRNASel binding protein (Mas) | Dotblot | 6 (3) | 2 (1) | 0 | 8 (2) | (1) |
| Anti-cytoplasmic Ro RNPs | ||||||
| Anti-Ro60/SS-A | ELISA, IB | 5 (3) | 8 (4) | 4 (11) | 17 (4) | (10–20) |
| Anti-Ro52 | ELISA, IB | 54 (27) | 44 (24) | 8 (21) | 106 (25) | ND |
| Anti-La/SS-B | ELISA, IB | 12 (6) | 6 (3) | 3 (8) | 21 (5) | (2–8) |
| Anti-U1 snRNP | IP, dotblot | 17 (9) | 7 (4) | 1 (3) | 25 (6) | (4–16) |
↵1-150 Approximately one third of anti-Jo-1 positive serum samples contain anti-tRNAHis autoantibodies16; most of the anti-PL12 positive serum samples contain anti-tRNAAlaautoantibodies.17
↵1-151 20% of DM sera, only a few anti-Mi-2 positive PM sera.43
↵1-152 PM = polymyositis; DM = dermatomyosits; IBM = inclusion body myositis; IB = immunoblotting; IP = immunoprecipitation.